Back to All Collaborations

Lilly 30×30: Improving Access to Quality Healthcare in Resource-Limited Settings

Active Since: 2016

Contributing to SDGs…

Improving access to treatment for diabetes, cancer and tuberculosis (TB) and contributing to a company-wide effort to reach 30 million people annually by 2030.

MEMBER COMPANIES

PARTNER ORGANISATIONS

  • Academia or research institute

    Academia Sinica

    Addis Ababa University

    Cebu Leprosy and Tuberculosis Research Foundation

    Infectious Disease Research Institute (IDRI)

    Institute of Human Virology

    Instituto da Criana Com Diabetes

    Massachusetts Institute of Technology

    McGill University

    Sabin Vaccine Institute

    Seattle Biomedical Research Institute

    South African Tuberculosis Vaccine Initiative

    Texas A&M University

    Tokyo University

    UK HIV Vaccine Consortium

    Universidade Federal do Rio Grande do Sul

    University of Delhi

    University of Washington

    Walter and Eliza Hall Institute of Medical Research

    Walter Reed Army Institute of Research

    International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B)

    Weill Medical College, Cornell University

  • Bilateral Organisations

    US Agency for International Development (USAID)

  • Global NGOs

    Aeras Global TB Vaccine Foundation

    Carlos Slim Health Institute

    European Vaccine Initiative

    International Diabetes Federation (IDF)

    PATH Malaria Vaccine Initiative (MVI)

    Population Services International (PSI)

    Project HOPE

    Academic Model Providing Access to Healthcare (AMPATH)

  • Local NGOs

    Donald Woods Foundation

  • Pharma company foundation

    Fundao Oswaldo Cruz (Fiocruz)

  • Pharma (Non-IPFMA Member)

    Gennova Biopharmaceuticals

  • Private foundation or development organization

    Public Health Foundation of India

    Fundao Oswaldo Cruz (Fiocruz)

    Bill and Melinda Gates Foundation

  • Generic manufacturers

    Abbott

  • Logistics and supply chain

    Academic Model Providing Access to Healthcare (AMPATH)

Objectives

  • Address gaps in care for cancer, diabetes and tuberculosis.
  • Improve access to care for 30 million people in resource limited settings each year by 2030.

What are the health needs and challenges?

In many parts of the world there exists a lack of timely diagnosis and access to quality care. This new five-year, $90 million investment in the Lilly Global Health Partnership will improve access to treatment for diabetes, cancer and tuberculosis (TB) and contribute to a company-wide effort to  reach 30 million people annually by 2030 (known as the Lilly 30×30). The expanded Lilly Global Health Partnership builds on and accelerates ongoing work of the Lilly MDR-TB and NCD Partnerships that have been running since 2003 and 2011 respectively.

Partnership activities and how they address needs and challenges

Working with expert partners, the Lilly Global Health Partnership helps people living in communities with limited resources in Brazil, China, India, Kenya, Mexico, Russia, South Africa and the U.S. Lilly is advancing its existing global health work in many of these communities while identifying new opportunities for partnership. Consistent with the company’s evidence-based approach (known as Research-Report-Advocate), the Lilly Global Health Partnership researches new models of care, reports findings and advocates for the scale-up of the most effective solutions to help more people.

The Lilly Global Health Partnership also includes a new $15 million commitment to the Infectious Disease Research Institute (IDRI). This will extend an eight-year collaboration to accelerate early-stage drug discovery and preclinical development for potential new TB medicines.

The Lilly Global Health Partnership and Lilly 30×30 extend and accelerate work done through major global health programs supported by Lilly and the Lilly Foundation over the past two decades. These include the Lilly MDR-TB Partnership, which included a decade-long transfer of manufacturing technology for TB medicines, support of early-stage TB drug discovery and improved care in high-burden countries. In 2011, the Lilly NCD Partnership was launched to help governments and key stakeholders improve diabetes prevention and care for people in need. The Lilly Global Health Partnership encompasses and expands these continuing efforts under a single heading.

In addition, Lilly works to improve global health through many other collaborative efforts, including ongoing product donations and funding for Academic Model Providing Access to Healthcare (AMPATH) in Kenya; support of the International Diabetes Federation’s Life for a Child program; and hunger relief efforts.

In order to reach 30 million people each year by 2030, Lilly will explore new approaches – in addition to the Lilly Global Health Partnership – within different areas of the business, including:

  • Drug discovery for diseases disproportionately affecting people in resource-limited settings;
  • Product delivery and packaging more appropriate for people in resource-limited settings;
  • Innovative business models, alternative product pricing and patient financial assistance to improve access to care;
  • Initiatives to strengthen health systems and local treatment capacity in communities with significant gaps in care; and
  • New patient education programs.

SDGs THE PARTNERSHIP CONTRIBUTES TO

SDG 3: Good Health and Wellbeing

  1. 3.3: Communicable Diseases & NTDs
  2. 3.4: NCDs (including mental health)

SDG 9: Industry Innovation and Infrastructure

SDG 17: Partnerships for the Goals